Nkarta, Inc.
NASDAQ: NKTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Paul J. Hastings
- Employees
- 108
- Headquarters
- South San Francisco, United States
- IPO year
- 2020
- Market cap
- $206.8M
- Website
- https://www.nkartatx.com
Loading NKTX…
Loading profile data…Frequently asked questions about NKTX
What does Nkarta, Inc. (NKTX) do?
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephri...
Where does NKTX trade?
Nkarta, Inc. (NKTX) trades on the NASDAQ.
What sector is NKTX in?
Nkarta, Inc. (NKTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nkarta, Inc.?
Paul J. Hastings is the chief executive officer of Nkarta, Inc. (NKTX).
Where is Nkarta, Inc. headquartered?
Nkarta, Inc. is headquartered in United States.
Does NKTX pay a dividend?
Nkarta, Inc. (NKTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NKTX go public?
Nkarta, Inc. (NKTX) completed its initial public offering in 2020.